Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma.
Barry
B
Ladizinski
Andrea
A
Bazakas
Elise A
EA
Olsen
D000368:Aged; D000982:Antipruritics / Q000627:therapeutic use*; D000077608:Aprepitant; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D009025:Morpholines / Q000494:pharmacology / Q000627:therapeutic use*; D064729:Neurokinin-1 Receptor Antagonists; D017294:Ondansetron / Q000008:administration & dosage; D010147:Pain Measurement; D011994:Recombinant Proteins / Q000627:therapeutic use; D013373:Substance P / Q000037:antagonists & inhibitors*
D000982:Antipruritics; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D011994:Recombinant Proteins; D000077608:Aprepitant; D013373:Substance P; D017294:Ondansetron